Daiichi Sankyo Company, Limited and AstraZeneca have received notification of acceptance by the U.S. Food and Drug Administration of the supplemental Biologics License Application of ENHERTU® for the treatment of adult patients in the U.S. with unresectable or metastatic HER2 positive breast cancer who have received a prior anti-HER2-based regimen.